Pharmacokinetics of sodium valproate in epileptic patients: Prediction of maintenance dosage by single-dose study

Autor: Schapel, G. J., Beran, R. G., Doecke, C. J., O'Reilly, W. J., Reece, P. A., Rischbieth, R. H. C., Sansom, L. N., Stanley, P. E.

Publikováno v: European Journal of Clinical Pharmacology; January 1980, Vol. 17 Issue: 1 p71-77, 7p

Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs

Autor: Ratnaike, R N, Schapel, G J, Purdie, G, Rischbieth, R H, Hoffmann, S

Erythrocyte (ENH3) and plasma (PNH3) ammonia levels, liver function tests and plasma valproate concentration were measured in 81 epileptic patients, comprising three therapeutic groups: Group 1 (23 patients) received sodium valproate (VPA) monotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fbea97fb53ab0143b37f167b7bff5b94
https://europepmc.org/articles/PMC1401093/

Skin rash and hydralazine

Autor: Schapel, G. J.

Publikováno v: Medical Journal of Australia; November 1984, Vol. 141 Issue: 11 p765-766, 2p

A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy.

Autor: Schapel GJ; Department of Pharmacology and Therapeutics, University of Wales College of Medicine and University Hospital of Wales, Heath Park, Cardiff, UK., Wallace SJ, Gordon GS

Publikováno v: Seizure [Seizure] 1997 Dec; Vol. 6 (6), pp. 479-83.

Melatonin response in active epilepsy.

Autor: Schapel GJ; Comprehensive Epilepsy Service, Queen Elizabeth Hospital, Woodville, Australia., Beran RG, Kennaway DL, McLoughney J, Matthews CD

Publikováno v: Epilepsia [Epilepsia] 1995 Jan; Vol. 36 (1), pp. 75-8.